john Given

[Ovarian Cancer Research Alliance @ocrahope]

The addition of immunotherapy to chemotherapy may significantly improve progression-free survival for certain endometrial cancer patients, a phase 3 study shows.

Results from the RUBY trial indicate that patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) primary advanced or recurrent endometrial cancer benefited from the addition of dostarlimab to standard carboplatin-paclitaxel chemotherapy.

The four-year progression-free survival rate was 57.9% with the combination treatment, compared with 15.7% for chemotherapy alone.

Read more about the research from corresponding author Matthew Powell, MD, of @WashUMedicine, and colleagues, including OCRA Scientific Advisory Committee (SAC) member Robert Coleman, MD, of @TexasOncology and @VaniamGroup.

@SitemanCenter @WashU
https://t.co/lm7rvw2cNW

[Irish Pharmacy Union @IrishPharmacy]

📢 IPU Welcomes Publication of Bill to allow Pharmacist-Led Contraception Service

The IPU has long advocated for the expansion of access to oral contraception to make it available to women direct from pharmacies. We therefore welcome the publication of the Health (Provision of Contraception Prescribing Service in Retail Pharmacy Businesses) Bill 2026, which will, if formally approved, allow pharmacists to continue an existing prescription for contraception for eligible patients for short-acting reversible contraception such as the oral contraceptive pill, transdermal patch and vaginal ring.

🔗 Read more at https://t.co/sUwOghPMA2

#ThinkPharmacy #Contraception #PharmacyIreland
@CarrollJennifer @NWCI

[TheJournal.ie @thejournal_ie]

The agency responsible for evaluating drug treatments in Ireland has said that a "significant price reduction" is expected for weight-loss medicine Mounjaro.
https://t.co/oqkvme5D3r

[Adela @adelapoite]

Futile Radiotherapy for Patients With Cancer Near the End of Life | Oncology | JAMA Network Open | JAMA Network https://t.co/3eSSuN6AnL

[Paul Cunningham @RTENewsPaulC]

From today’s “This week” programme: Value of early access to new medicines questioned by Director of National Centre for Pharmacoeconomics https://t.co/adBYkJZE4I

[RTÉ News @rtenews]

Professor Michael Barry said that new medicines, such as those for rare diseases, are "very expensive" and "the reality is many of these drugs don't work very well." https://t.co/QhuTdts8Rr

[The Ditch @wereontheditch]

After two patients of a surgeon at Beaumont suffered “devastating neurological outcomes”, a doctor-led committee at the hospital – in a letter obtained by The Ditch – asked a clinical director to consider stopping the surgeon performing certain surgeries.

https://t.co/EcQ6RyLVCK

[University of Galway Surgery 🔬🧬 @GalwaySurgery]

Warmest congratulations to Prof Michael Kerin on his election as President of the @RCSI_Irl.
We wish him all the best & every success in his new role.
We look forward to Professor Kerin's rewarding and impactful tenure as he begins his Presidency.
#surgicalexcellence

[Charlie Weston @CWeston_Indo]

Ministers approve €45,500 pay rise for CEO of VHI amid claims premiums are spiralling https://t.co/3S8ZDFLm7E

[Papa Heme @Papa_Heme]

Yes, Tec definetly made these healthy "patients" better

CRS occurred in 32/45 Tec-treated patients (71.1%); all were grade 1/2. No ICANS or deaths occurred. Grade ≥3 AEs included neutropenia (Tec 16/45, 36% [gr4, n=8]; Rd 11/14, 79% [gr4, n=4]), thrombocytopenia (Tec 2/45, 4% [gr4, n=1]; Rd 2/14, 14%), infections (Tec 9/45, 20%; Rd 3/14, 21.4%) and ALT/AST elevation (Tec 5/45, 11%; Rd 1/14, 7%). Grade ≥3 lymphopenia occurred only in the Tec arm (4/45, 9% [gr4, n=1]) as well as one gastrointestinal AE (2.2%). All Tec-treated patients received IVIG.

[Benlazar S M A @smbenlazar]

TECLISTAMAB IMPROVES DEPTH OF RESPONSE AND PFS VERSUS LENALIDOMIDE-DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA https://t.co/kcMXGzYpiJ #mmsm #EHA26

[Shaun Lintern @ShaunLintern]

🚨 Hundreds of patients operated on by a rogue surgeon could have their care reviewed after the latest inquiry criticises past reviews as inadequate amid claims of a cover-up at Englands once safest hospital:
https://t.co/K108r8hNjj

[Irish Multiple Myeloma Society @irishmyelomasoc]

Speaking at this years #MultipleMyelomaIreland Family & Patient Information Day on May 15th, are IMMS Executive Committee members Prof. Paul Browne, Prof. Siobhan Glavey and Dr. Janusz Krawczyk.
Register here: https://t.co/obsm1dqM6L

#Healthcare #IrishMultipleMyelomaSociety

[Irish Pharmacy Union @IrishPharmacy]

📢 IPU UCC Medicines Shortages Survey
The survey can be accessed here: https://t.co/oP63I11Cof

This is one of our most important surveys each year, and your insights help shape our advocacy efforts. By taking part, you help us highlight the challenges pharmacies face in managing shortages and ensure this issue remains a priority for policymakers.

Your input makes a difference – complete the survey today! 📝 ✅

[Vincent Rajkumar @VincentRK]

This is what the myeloma community as a whole (Pharma, Patients, Investigators, NIH, FDA, and Foundations) have collectively accomplished. 👇

[HSEWestNorthWest @HSE_West_NWest]

A significant milestone has been reached for University Hospital Galway with the appointment of Perkins & Will and Cullen Payne Architects to lead the design of two new ward blocks delivering 300 additional beds.
#Healthcare #Infrastructure

[Irish Pharmacy Union @IrishPharmacy]

A key step forward for community pharmacy. 💊

🧾 New legislation introducing electronic record keeping has now been signed, allowing prescriptions sent electronically to be retained in digital form in defined circumstances.

This will reduce paper-based processes and support more efficient ways of working, while preparing pharmacy for future digital developments.

Read more ➡️ https://t.co/o6iKd8kIaf

#ThinkPharmacy #PharmacyIreland #PharmacyLegislation #CommunityPharmacy

[TheJournal.ie @thejournal_ie]

The new machine, the first of its kind to be installed in Ireland, will dramatically reduce the time it takes to reach a diagnosis from days to a matter of hours, the NBCRI said.
https://t.co/rP74Tumk23

[Alex Rampotas @ARampotas]

These type of curves would have been unimaginable for any haematologists or patients 10years ago. Myeloma is becoming a highly treatable cancer with excellent prognosis

Which one is next? Myelofibrosis?

[Peter Forsberg MD @ForsbergMD]

Our data from @ColoradoBlood is out now. We developed an approach using dex for excessive lymphocyte expansion after Cilta-Cel. Instituted along with more stringent bridging we subsequently observed improvements in non-relapse mortality and reduced severe atypical neurotox events